jeudi 28 février 2019

Onco Actu du 28 février 2019

1. BIOLOGIE

Cancer genes’ age and function strongly influence their mutational status [eLife]

HeLa Cells from Different Labs Vary in Genetics, Phenotype [The Scientist]

4.2 DÉP., DIAG. & PRONO. - GÉNOME

Yes we can, EUCANCan! [VHIO]

5. TRAITEMENTS

Proteasome Inhibitors, Refined [In The Pipeline]

Lab-grown mini tumors could help identify personalized treatments for people with rare cancers [UCLA]

5.1 TRAITEMENTS - PRÉ-CLINIQUE

Blocking DNA repair restores sensitivity of brain tumors to treatment in mice [NIH]

5.10 TRAITEMENTS - ESSAIS

AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class first [Fierce Pharma]

AstraZeneca's PARP drug succeeds in pancreatic cancer study [Biopharma Dive]

5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES

Immatics, Roche ally to trial Tecentriq with cell therapy [Fierce Biotech]

Scientists devise strategies to counteract T cell exhaustion in CAR T cancer therapies [La Jolla Immunology]

Driving CAR T cell translation forward [Science Translational Medicine]

5.2 PHARMA

Parexel, on a hiring spree, nabs another key FDA staffer as it bolsters oncology execs [Fierce Biotech]

Parexel recruits top FDA oncology expert Amy McKee for new R&D initiative [EndPoints]

5.2.1 PHARMA - PARTENARIATS

Servier terminates CTI cancer pact following clinical failure [Fierce Biotech]

5.2.2 PHARMA - FUSIONS & ACQUISITIONS

Bristol-Myers’ largest shareholder comes out against its $74B Celgene buyout, raising a ‘real risk’ of torpedoing the deal [EndPoints]

Top Bristol-Myers shareholder comes out against $74 billion Celgene deal [Reuters]

5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)

FDA experts turn thumbs down on Karyopharm’s troubled pitch for an accelerated OK — but not all of them [EndPoints]

5.9 AACR

Prostate Cancer Patients With Cardiovascular Disease Had Higher Mortality After Starting Abiraterone Acetate [AACR]

5.9.10 AACR - COLORECTAL

Survey of Young-onset Colorectal Cancer Patients Suggests Misdiagnosis May Be Common [AACR]

5.9.12 AACR - BIOPSIES LIQUIDES

Liquid Biopsy-based Test As Good As Tissue-based Test for Identifying Treatment for Lung Cancer [AACR]

Guardant’s blood test might replace biopsies for some lung cancer patients, study says [STAT]

5.9.9 AACR - IMMUNOTHÉRAPIES

Dietary Factors Affecting Gut Microbiome May Influence Response to Immunotherapy in Melanoma Patients [AACR]

6. LUTTE CONTRE LES CANCERS

Data sharing will be a major thrust of Trump’s $500 million childhood cancer plan [Science]

6.1 OBSERVATION

Hyperglycemia and Aggressive Prostate Cancer Risk [Cancer Research Catalyst]

Nearly half of all children with cancer go undiagnosed and untreated [Thee Guardian]

6.10.1 POLITIQUES (USA)

In muted hearing, pharma execs dodge attempts to pin blame for high prices [STAT]

Pharma companies want the government to do something about high drug prices, so long as it's not forcing them to lower their drug prices [Business Insider]

In landmark hearing, drugmakers and lawmakers agree that US policy on drug pricing is ripe for change — but there’s no consensus on much else [EndPoints]

U.S. senators tell drug company executives pricing is 'morally repugnant' [Reuters]

6.4 MÉDICO-ÉCO

Cancer Complications: Confusing Bills, Maddening Errors And Endless Phone Calls [NPR]

6.6 PUBLICATIONS

High-profile subscription journals critique Plan S [Nature]

6.8 COMMUNICATION

Netflix pulls controversial documentary that claims root canals cause cancer [The Guardian]

6.9 CONTROVERSES

Simon Rule and Steven LeGouill: Bureaucracy is strangling clinical research [BMJ]